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ABSTRACT 
A new series of pyrazole derivatives were designed by docking into vascular endothelial growth factor receptor-
2 (VEGFR-2) kinase active site. The designed compounds were synthesized and evaluated for in vitro antiprolif-
erative activity against HT-29 colon and PC-3 prostate cancer cell lines, and angioinhibitory activity in chori-
oallantoic membrane (CAM) model. Based on the obtained antiproliferative activity results of in vitro and CAM 
assay, compounds 4b, 4c, 4f, 5b, 5c and 5f were selected, and tested for anticancer activity using in vivo ehrlich 
ascites carcinoma (EAC) bearing mice. Compound 5c showed the highest in vitro antiproliferative activity 
against HT-29 and PC-3 with IC50 values of 6.43 µM and 9.83 µM respectively and comparable to reference 
drug Doxorubicin. Results of in vivo anticancer activity revealed that compound 5c showed the highest percent-
age increase in life span ( %ILS), and mean survival time (MST) with 75.13 % and 32.4 ± 0.53 days respective-
ly. Moreover, compound 5c demonstrated significant reduction of microvessel density (MVD) in CAM assay. In 
silico prediction of toxicities, and drug score profiles of designed compounds are promising. A correlation made 
between the results obtained by antiproliferative study and molecular docking studies suggest that the synthe-
sized compounds may be beneficial as molecular scaffolds for antiproliferative activity.  
 
Keywords: Pyrazolyl tetrazole acetic acids, antiproliferative activity, molecular modeling, VEGFR-2  
 
 
 
 
INTRODUCTION 
Cancer is a major chronic disease, known 
for second leading cause of death worldwide. 
As per the world cancer report issued by the 
international agency for research on cancer 
(IARC), the cancer rates could increase by 
50 % to 15 million new cases by 2020. In re-
cent years, small molecules are widely ex-
plored as anticancer agents and among them 
pyrazoles have attracted significant scientific 
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attention, because of their unique structure 
(Havrylyuk et al., 2009; Liu et al., 2012, 
2011; Insuasty et al., 2010; Congiu et al., 
2010; Omprakash et al., 2013; Liu et al., 
2010). On the other hand, tetrazole and its 
derivatives are reported to possess medicinal 
properties such as anticancer (Arshad et al., 
2014; Gundugola et al., 2010; Sai-
pavankumar et al., 2011; Mahesh et al., 
2014), antimicrobial (Rostom et al., 2009) 
and anti-inflammatory (Bekhit et al., 2004). 
In the earlier study, we synthesized a series 
of novel pyrazolyl tetrazoles based on bi-
oisosterism and reported them as cyclooxy-
genase-2 (COX-2) selective inhibitors 
(Swetha et al., 2013). COX-2 is an inducible 
enzyme that is up regulated by a various fac-
tors, which include growth factors, cytokines 
and tumor promoters (Williams et al., 1999). 
This enzyme is prominently over expressed 
in cells, which contribute induction of vascu-
lar endothelial tubular morphogenesis (Tusjii 
et al., 1998). Moreover, in recent years, the 
involvement of COX- 2 enzyme in carcino-
genesis was reported by several research 
groups (Fosslien, 2000; Subbaramaiah et al., 
2003). Inspired by this information and con-
tinued our research on pyrazoles, herein we 
started our work with introduction of te-
trazole ring on the pyrazole, and allowed 
ethyl chloroacetate to react with acidic nitro-
gen of tetrazole to yield desired pyrazolyl te-
trazole acetic acids. 
Vascular endothelial growth factor 
(VEGF) and their receptor (VEGFR) are 
pathologically involved in various processes 
of angiogenesis (Folkman, 1995; Carmeliet 
and Jain, 2000) which include endothelial 
cell (EC) migration, increased vascular per-
meability, survival and proliferation (Robin-
son et al., 2000). Among the receptors, 
VEGFR-2 is more expressed in ECs, and is a 
key growth factor of various tumor angio-
genesis. Consequently, in recent years, this 
receptor has gained much scientific focus, as 
target for the design of new anticancer agents 
(Hiroyuki et al., 2006) and sunitinib (SU-
6668), sorafenib (BAY-43-9006) and 
vandetanib (ZD-6474) are some of clinically 
used VEGFR-2 inhibitors. Previously, sever-
al research groups have been reported pyra-
zole derivatives as potent VEGFR-2 kinase 
inhibitors (Miyamoto et al., 2013). 
Based on the above consideration, we de-
signed a new series of pyrazole derivatives 
using molecular docking studies with the 
help of software MOE 2008 into the active 
site of VEGFR-2 kinase. Virtual screening 
was focused on experimental molecules 
showing significant interactions as that of 
marketed drugs used in clinical practice, to 
the specific active site amino acids of the re-
ceptor. Promising molecules in this docking 
study were synthesized as given in the Fig-
ure 1. The synthesized compounds were 
screened for in vitro antiproliferative activity 
against two cell lines namely HT-29 colon 
and PC-3 prostate and in vivo using chori-
oallantoic membrane (CAM) model. Based 
on the obtained results of these assays, com-
pounds 4b, 4c, 4f, 5b, 5c and 5f were tested 
for in vivo anticancer using ehrlich ascites 
carcinoma (EAC) bearing mice. 
 
MATERIALS AND METHODS 
Chemistry 
All reagents were purchased from com-
mercial sources. Melting points were uncor-
rected and determined in one end open capil-
lary tubes using Analab melting point appa-
ratus. The IR spectra were recorded on Shi-
madzu FTIR 8400S spectrophotometer and 
expressed in wave numbers (cm-1), using 
1 % potassium bromide discs. 1H NMR spec-
tra were recorded on Varian 400 MHz spec-
trometer using DMSO-d6 as solvent and tet-
ramethylsilane as an internal standard. The 
13C NMR spectra of the synthesized deriva-
tives were recorded on Varian Gemini 
100 MHz spectrophotometer and mass spec-
tra were recorded on Agilent 6430 triple 
quadruple LC-MS system. TLC was per-
formed using E.Merck 0.25 mm silica gel 
plates and visualization of spots was accom-
plished with UV light (256 nm).  
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Figure 1: The total synthetic pathway. Reagents and conditions: (a) NH2OH.HCl, NaOH, EtOH, reflux, 
2h; (b) acetic anhydride, reflux, 1h; (c) NaN3, DMF, triethyl ammonium chloride, reflux, 24-48 h; (d) 
ethyl chloroacetate, K2CO3, dry acetone, reflux, 4 h; and (e) NaOH, EtOH, reflux, 4h 
 
 
General procedure for the synthesis of 1-
phenyl-3-aryl-1H-pyrazole-4-carbonitriles 
(3) 
To a solution of compound 1 (10 mmol) 
in 20 mL ethanol, was added hydroxylamine 
hydrochloride (20 mmol), sodium hydroxide 
(20 mmol) and heated under reflux for 2 h. 
The reaction mixture was cooled, added to 
100 mL of water and neutralized with 0.1N 
hydrochloric acid. The separated solid was 
filtered and recrystallized from 90 % ethanol 
to give compound 2. 
A mixture of compound 2 (10 mmol) and 
freshly distilled acetic anhydride (100 mmol) 
was heated strongly at 140-150 °C for 1 h to 
give compound 3. The reaction mixture was 
cooled to room temperature and added to 
crushed ice with stirring. The solid separated 
was filtered and recrystallized from 90 % 
ethanol. 
General procedure for the synthesis of 5-(1-
phenyl-3-aryl-1H-pyrazol-4-yl)-2H-
tetrazoles (4a-4g)  
A mixture of pyrazole nitrile 3 
(10 mmol), sodium azide (20 mmol), and tri-
ethyl ammonium chloride (20 mmol) was 
taken in 15 mL of DMF and refluxed for 24-
48 h. The completion of reaction was moni-
tored by TLC. The reaction mixture was 
cooled, added to 50 mL of water and acidi-
fied with 0.1N hydrochloric acid. The sepa-
rated solid was filtered and recrystallized 
from chloroform-ethanol mixture to give 
compound 4. Physical and spectroscopic data 
of compounds 4a-4g have been reported 
elsewhere (Swetha et al., 2013). 
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General procedure for the synthesis of [5-(1-
phenyl-3-aryl-1H-pyrazol-4-yl)-2H-tetrazol-
2-yl] acetic acids (5a-5g) 
To a mixture of compound 4 (10 mmol) 
and anhydrous potassium carbonate 
(10 mmol) in 20 mL of dry acetone, was 
added ethyl chloroacetate (12 mmol) and re-
fluxed for 4 h. The solvent was removed by 
evaporation under reduced pressure using a 
Rotary evaporator and the solid residue ob-
tained was recrystallized from 90 % ethanol 
to give pyrazolyl tetrazole ester. 
A mixture of above ester (10 mmol) and 
25 % aqueous sodium hydroxide (5 mL) was 
taken in 90 % ethanol and refluxed for 4 h. 
The reaction mixture was cooled, added to 
50 mL of water and neutralized with dilute 
hydrochloric acid. The solid separated was 
filtered and recrystallized from 90 % ethanol 
to give compound 5. 
2-(5-(1, 3-diphenyl-1H-pyrazol-4-yl)-2H-
tetrazol-2-yl) acetic acid (5a) 
Yellow crystals, yield 60 %, mp 220-
222 °C. IR (KBr, cm-1): 3456 (OH), 3004 
(CH aromatic), 1731 (C=O), 1596 (C=N). 1H 
NMR (DMSO-d6, 400 MHz, δ ppm): 10.61 
(s, 1H, COOH), 9.22 (s, 1H, pyrazole), 8.02 
(d, 2Ar-H, J=7.82 Hz), 7.76 (m, 2Ar-H), 
7.57 (t, 2Ar-H, J=8.02 Hz), 7.42 (m, 4Ar-H), 
5.82 (s, 2H, CH2COOH). 13C NMR (DMSO-
d6, 100 MHz, δ ppm): 166.2 (COOH), 156.8 
(tetrazole carbon), 137.9, 134.5, 129.3, 
128.8, 127.1, 126.9, 126.5, 125.4, 124.1, 
119.4, 104.3, 47.4 (CH2). MS (m/z): 346 
(M+).  
2-(5-(3-(2-chlorophenyl)-1-phenyl-1H-
pyrazol-4-yl)-2H-tetrazol-2-yl) acetic acid 
(5b) 
White powder, yield 67 %, mp 196-
198 °C. IR (KBr, cm-1): 3457 (OH), 3080 
(CH aromatic), 1723 (C=O), 1598 (C=N), 
754 (C-Cl). 1H NMR (DMSO-d6, 400 MHz, 
δ ppm): 10.92 (s, 1H, COOH), 9.30 (s, 1H, 
pyrazole), 7.96 (d, 2Ar-H, J = 8.21 Hz), 7.42 
(m, 4Ar-H), 7.51 (d, 2Ar-H, J = 8.25 Hz), 
7.53 (t, 1Ar-H, J = 7.42 Hz), 5.52 (s, 2H, 
CH2COOH). 13C NMR (DMSO-d6, 100 
MHz, δ ppm): 165.8 (COOH), 157.7 (te-
trazole carbon), 139.5, 134.1, 130.1, 129.4, 
128.2, 127.8, 126.9, 126.1, 125.9, 124.5, 
123.8, 119.6, 105.5, 49.5 (CH2). MS (m/z): 
381 (MH+).  
2-(5-(3-(4-chlorophenyl)-1-phenyl-1H-
pyrazol-4-yl)-2H-tetrazol-2-yl) acetic acid 
(5c) 
White powder, yield 66 %, mp 195-
197 °C. IR (KBr, cm-1): 3448 (OH), 3124 
(CH aromatic), 1724 (C=O), 1596 (C=N), 
759 (C-Cl). 1H NMR (DMSO-d6, 400 MHz, 
δ ppm): 10.50 (s, 1H, COOH), 9.12 (s, 1H, 
pyrazole), 7.95 (d, 2Ar-H, J = 8.21 Hz), 7.62 
(m, 4Ar-H), 7.54 (d, 2Ar-H, J = 8.21 Hz), 
7.45 (t, 1Ar-H, J = 7.43 Hz), 5.50 (s, 2H, 
CH2COOH). 13C NMR (DMSO-d6, 100 
MHz, δ ppm): 167.2 (COOH), 157.5 (te-
trazole carbon), 138.5, 133.5, 129.5, 129.0, 
128.2, 127.8, 127.2, 126.8, 126.1, 118.2, 
103.5, 48.5 (CH2). MS (m/z): 381 (MH+).  
2-(5-(3-(4-methylphenyl)-1-phenyl-1H-
pyrazol-4-yl)-2H-tetrazol-2-yl) acetic acid 
(5d) 
Light yellow powder, yield 65 %, mp 
210-212 °C. IR (KBr, cm-1): 3447 (OH), 
3126 (CH aromatic), 2920 (CH aliphatic), 
1735 (C=O), 1596 (C=N). 1H NMR (DMSO-
d6, 400 MHz, δ ppm): 11.03 (s, 1H, COOH), 
9.07 (s, 1H, pyrazole), 7.95 (d, 2Ar-H, J = 
8.1 Hz), 7.61-7.57 (m, 4Ar-H), 7.49 (d, 2Ar-
H, J = 8.42 Hz), 7.44 (t, 1Ar-H, J =7.20 Hz), 
5.52 (s, 2H, CH2COOH), 2.50 (s, 3H, CH3). 
13C NMR (DMSO-d6, 100MHz, δ ppm): 
166.8 (COOH), 156.5 (tetrazole carbon), 
136.4, 133.4, 132.4, 128.9, 128.6, 127.8, 
127.2, 126.9, 125.7, 119.5, 105.6, 48.8 
(CH2), 22.7 (CH3). MS (m/z): 360 (M+).  
2-(5-(3-(2-methoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)-2H-tetrazol-2-yl) acetic acid 
(5e) 
Cream powder, yield 68 %, mp 184-
186 °C. IR (KBr, cm-1): 3417 (OH), 3127 
(CH aromatic), 2845 (CH aliphatic), 1740 
(C=O), 1543 (C=N), 1027 (C-O). 1H NMR 
(DMSO-d6, 400 MHz, δ ppm): 10.54 (s, 1H, 
COOH), 9.24 (s,1H, pyrazole), 8.20 (d, 2Ar-
H, J = 7.86 Hz ), 7.82 (d, 2Ar-H, J = 8.98 
Hz), 7.65(t, 2Ar-H, J = 8.06 Hz), 7.46 (t, 
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1Ar-H, J = 7.43 Hz), 7.23 (d, 2Ar-H, J = 
8.61 Hz), 5.64 (s, 2H, CH2COOH), 3.81 (s, 
3H, OCH3). 13C NMR (DMSO-d6, 100 MHz, 
δ ppm): 167.5 (COOH), 158.8 (tetrazole car-
bon), 148.9, 139.2, 134.8, 129.9, 128.7, 
127.9, 127.4, 124.9, 119.3, 112.3, 120.3, 
107.8, 53.4 (CH2), 52.6 (OCH3). MS (m/z): 
376 (M+).  
2-(5-(3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)-2H-tetrazol-2-yl) acetic acid 
(5f) 
Cream powder, yield 68 %, mp 185-
187 °C. IR (KBr, cm-1): 3417 (OH), 3128 
(CH aromatic), 2842 (CH aliphatic), 1739 
(C=O), 1593 (C=N), 1026 (C-O). 1H NMR 
(DMSO-d6, 400 MHz, δ ppm): 10.43 (s, 1H, 
COOH), 9.25 (s, 1H, pyrazole), 8.13 (d, 2Ar-
H, J = 7.85 Hz ), 7.82 (d, 2Ar-H, J = 8.99 
Hz), 7.63 (t, 2Ar-H, J = 8.09 Hz), 7.43 (t, 
1Ar-H, J = 7.43 Hz), 7.01 (d, 2Ar-H, J = 
8.60 Hz), 5.63 (s, 2H, CH2COOH), 3.81 (s, 
3H, OCH3). 13C NMR (DMSO-d6, 100 MHz, 
δ ppm): 166.5 (COOH), 158.6 (tetrazole car-
bon), 149.5, 138.5, 135.1, 129.7, 128.3, 
127.5, 126.0, 124.5, 118.4, 113.5, 107.5, 
54.5 (CH2), 53.5 (OCH3). MS (m/z): 376 
(M+).  
2-(5-(3-(2-naphthyl)-1-phenyl-1H-pyrazol-4-
yl)-2H-tetrazol-2-yl) acetic acid (5g)  
Yellow powder, yield 62 %, mp 210-
212 °C. IR (KBr, cm-1): 3498 (OH), 3051 
(CH aromatic), 1720 (C=O), 1593 (C=N). 1H 
NMR (DMSO-d6, 400 MHz, δ ppm): 10.84 
(s, 1H, COOH), 9.04 (s, 1H, pyrazole), 8.22 
(d, 2Ar-H, J = 8.0 Hz), 8.00-7.94 (m, 3Ar-
H), 7.71-7.65 (m, 2Ar-H), 7.60-7.55 (m, 
4Ar-H), 7.40 (t, 1Ar-H, J = 7.23 Hz), 5.82 (s, 
2H, CH2COOH). 13C NMR (DMSO-d6, 100 
MHz, δ ppm): 167.8 (COOH), 157.9 (te-
trazole carbon), 140.2, 137.6, 132.4, 131.4, 
129.4, 128.5, 127.8, 126.6, 126.4, 125.8, 
124.2, 123.4, 118.6, 103.7, 52.7 (CH2). MS 
(m/z): 396 (M+).  
 
Pharmacological screening  
In vitro antiproliferative activity 
The antiproliferative activity of synthe-
sized compounds was evaluated against HT-
29 colon cancer and PC-3 prostate cancer 
cell lines as described in the literature (Lem-
bege et al., 2008; Chen et al., 2015). Tumor 
cell lines were grown in DMEM media sup-
plemented with 20 % heat-inactivated fetal 
bovine serum (FBS), 100 IU/mL penicillin, 
100 mg/mL streptomycin and 2 mM-Glu-
tamine. The cell cultures were maintained in 
a humidified atmosphere with 5 % CO2 at 
37 °C. The cells were subcultured twice a 
week, seeding at a density of about 2×103 
cells/mL. Cell viability was determined by 
the trypan blue dye exclusion method. 5×103 
cells/well (HT-29 and PC-3) were inoculated 
in 96-well microtiter plate for 24 h, before 
treatment with the compounds, cells were al-
lowed to attachment with wall of the plate. 
Test compounds were dissolved in dimethyl 
sulfoxide (DMSO), further diluted with sa-
line to appropriate volume. Different concen-
trations of the compound under test (0.5, 1, 
5, and 10 μM/mL) were added to the wells, 
and the cells were incubated at 37 °C in a 
5 % CO2 incubator for 48 h. The cells were 
treated with 10 μL MTT dye solution (5 
mg/mL) for 4 h cultivation. The media along 
with the MTT solution was washed with 
100 μL of DMSO solution. The absorbance 
of formazan solution was measured at 
540 nm with an automatic multi-well plate 
reader (Victor3TM, Perkin-Elmer, and USA). 
Percentage inhibition of proliferation was 
calculated as a fraction of control (without 
drug)  
 
%Growth = Absorbance of test/Absorbance 
of control×100 
% Inhibition = 100- % Growth 
 
Angioinhibitory activity by CAM assay 
CAM assay was performed according to 
the previously described method (Chandru et 
al., 2007). The fertilized eggs were divided 
into sixteen groups and in each group a min-
imum of six eggs were used. Vehicle control 
group was treated with 0.1 % DMSO, saline 
treated group and compounds treated groups 
were maintained separately and observed. 
For a period of 5 days, eggs in all the groups 
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were incubated separately at 37 °C in humid-
ified and sterile conditions. A small window 
was made on egg shell under aseptic condi-
tions and observed for proper development 
of the embryo. The windows were resealed 
with adhesive tape and incubation was con-
tinued. On day 11, the windows were opened 
and the test compounds and vehicle were 
loaded on the cover slips separately, air-
dried, and inverted over the CAM. The win-
dows were resealed and returned to the incu-
bator. The windows were opened and in-
spected on day 13 and observed for changes 
of MVD in the area under cover slip and 
studied under a microscope for avascular 
zone. 
 
In vivo antitumor activity 
The experimental protocol for the phar-
macological screening on mice was done 
with an Institutional Animal Ethics Commit-
tee, Guru Nanak Institute of Pharmacy, Hy-
derabad, India (Reg no: 1374/ac/10/ 
CPCSEA). Male Albino Swiss mice weigh-
ing between 20-25 g were selected for 
screening of anticancer activity. Animals 
were kept and maintained under standard la-
boratory conditions and provided free access 
to food and water ad libitum. The selected 
animals were allowed to acclimatize to the 
laboratory environment for seven days prior 
to in vivo experiment. The selected animals 
were divided into 9 groups each comprised 
of 12 animals. EAC cells were obtained from 
the donor mice and were suspended in a 
known quantity of 0.9 % NaCl normal sa-
line. The cell count was adjusted to 2×106 
cells/mL. All the groups were treated with 
EAC cells through intraperitonial (ip) route 
except the normal control group on day zero. 
Group I was treated with normal saline (5 
mL/ kg body weight) and group II as EAC 
control. Group III was treated with standard 
drug 5-Fluorouracil (20 mg/kg body weight). 
The test compounds were administered 
through ip at dose of 50 mg/kg body weight 
in groups IV-IX, respectively. All the test 
compounds and 5-Fluorouracil were treated 
daily for 9 days starting 1 day after tumor 
transplantation. After 9 days, six animals 
from each group were sacrificed. The tumor 
volume and cell count parameters were rec-
orded. Mean survival time (MST) for re-
maining six mice of each group was record-
ed (Dhamija et al., 2013). 
The groups and design of experiment: 
Group I: Normal saline 
Group II: EAC (2×106 cells) 
Group III: EAC (2×106 cells) + 5-Fluorouracil 
Group IV: EAC (2×106 cells) + Compound 4b  
Group IV: EAC (2×106 cells) + Compound 4c  
Group V: EAC (2×106 cells) + Compound 4f  
Group VI: EAC (2×106 cells) + Compound 5b  
Group VII: EAC (2×106 cells) + Compound 5c  
Group VIII: EAC (2×106 cells) + Compound 5f  
 
Tumor weight and cell count 
The 6 mice were dissected and the total 
ascetic fluid was harvested from peritoneal 
cavity. The volume was measured by taking 
it in a graduated centrifuge tube and the 
packed cell volume noted by centrifuge at 
1000 rpm for 5 min and viable cells were 
checked by trypan blue dye exclusion test 
and cells were counted in Neubauer counting 
chamber. 
 
MST and percentage increase in life span 
( %ILS) 
The activity of the pyrazole compounds 
on tumor growth was evaluated by recording 
the mortality within the observation period. 
Percentage increase in life span (ILS) was 
calculated by using the following formula. 
 
 % ILS = (MST of treated group - MST of 
control group ×100) / MST of control group 
 
MST = (Survival time of each mice in a 
group (days)) / Total number of mice 
Molecular modeling  
Docking was performed on windows 
2002 using MOE 2008.10 version. VEGFR-
2 kinase was retrieved from the protein data 
bank (PDB code: 2XIR) and the receptor 
was visualized using sequence option and 
further co-factors were deleted. The partial 
charge of protein was adjusted with the help 
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of force field method AMBER 99. Later, the 
protein was subjected to 3D protonation at 
cut off 12.0, and further hydrogen was added 
according to standard geometry and the re-
ceptor was energy minimized using force 
field MMFF94x at 0.01 KJ mole gradients. 
The ligand structures were written by using a 
builder module, and adjusting the partial 
charges using Hamilton MMFF94 force field 
method and subsequently 3D protonation 
and hydrogen addition was performed ac-
cording to standard geometry. Ligands were 
energy minimized at cut off 12 using force 
field MMFF94x at 0.01KJ mole gradient. 
Docking was performed using the option 
simulation followed by dock on selected ac-
tive site amino acids using sequence option, 
and eventually docked using setting options 
such as receptor and solvent, alpha triangle, 
selected residues, affinity dG, force field re-
finement and best 30 pose. After obtaining 
docking results, out of the 30 best posed re-
sults for each chemical structure, best pose 
was retained. The resultant best pose score 
values in the series were used for analysis of 
docking and interaction (Garofalo et al., 
2011).  
 
Toxicity prediction by bioclipse  
Bioclipse open tox software was run on 
windows 7 platform, which process the 
chemical structure by interacting with known 
toxic compounds for predictive toxicology. 
Chemical structures were imported in mole 
file into bioclipse navigator which was fur-
ther processed with different interacting 
software modules such as mutagenicity, car-
cinogenicity, aquatic toxicity, site of metabo-
lism and Cytochrome P450 proteochemo-
metric (CYP PCM). After ballooning, ob-
tained detailed decision support in portable 
document format (Spjuth et al., 2011, 2007). 
 
Assessment of lipophilicity and drug score 
profiles  
Shredding of each molecule at every ro-
tatable bond led to a set of core fragments. 
These in turn were used to reconstruct all 
possible larger fragments which could be the 
substructure of the original molecule. After-
ward, a search process of substructure de-
termined the occurrence frequency of every 
one of the fragment (constructed and core 
fragments) within all traded dugs of 3300 as 
well as 15,000 commercially available chem-
icals (Fluka) to predict lipophilicity and drug 
score profiles (Ali et al., 2013). 
 
RESULTS AND DISCUSSION 
Chemistry 
According to Figure 1, pyrazole-4-car-
baldehyde 1 was reacted with hydroxylamine 
hydrochloride to give corresponding pyra-
zolyl oxime 2 by established reaction. The 
resultant product was confirmed by appear-
ance of a peak at 1620 cm-1 and disappear-
ance of aldehyde peak at 1670 cm-1 in IR 
spectra. The pyrazolyl oxime was heated 
with acetic anhydride at 140-150 °C for 2 h 
to give pyrazole nitrile 3, which was con-
firmed by a sharp peak around 2200 cm-1 in 
IR spectra. The compound 3 was cyclized 
with sodium azide in the presence of triethyl 
ammonium chloride under reflux for 24-36 h 
to yield 4a-4g. The formation of these com-
pounds was confirmed by disappearance of 
peak at 2200 cm-1 and appearance of NH 
peak at 3400-3420 cm-1 in IR spectra. 1H 
NMR spectra of compounds showed a sin-
glet around δ 9.02 for pyrazole proton and 
the peaks for aromatic protons appeared in 
the range of δ 7.00-8.00 validated formation 
of desired compounds. The compounds 4a-
4g were treated with ethyl chloroacetate 
yielded corresponding esters, which were 
hydrolyzed with sodium hydroxide to give 
desired compounds 5a-5g. The structures of 
final compounds were confirmed using 
FTIR, 1H NMR, 13C NMR, and mass spectral 
data. In IR spectra, C=O absorption band of 
COOH appeared between 1720- 1730 cm-1 
and 1H NMR of compounds showed a singlet 
between δ 10.50 to11.00 for COOH proton, a 
singlet around δ 9.00 for pyrazole proton, a 
singlet at δ 5.50-5.80 for two methylene pro-
tons of CH2COOH and the peaks for aro-
matic protons appeared in the range of δ 
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7.00-8.50 confirmed the structures. 13C NMR 
spectra of compounds showed a peak in the 
range of δ 47.0-54.0 due to CH2 carbon, the 
carbon of COOH appeared around δ 167.0, a 
peak around δ 157.0 due to tetrazole carbon 
and aromatic carbons appeared in the range 
of δ 104.0-150.0 confirmed the formation of 
desired compounds. This was further more 
supported by mass spectral data. The physi-
cal and spectral data of individual com-
pounds were given under experimental sec-
tion. 
 
Pharmacological screening  
In vitro antiproliferative activity 
Antiproliferative screening of the synthe-
sized compounds 4a-4g and 5a-5g was car-
ried out by in vitro method using MTT assay 
against two cell lines namely HT-29 (colon) 
and PC-3 (prostate). Doxorubicin was used 
as reference drug. From percentage inhibi-
tion IC50 values were calculated in µM and 
shown in Table 1. Overall, better antiprolif-
erative activity was observed for 5a-5g series 
as compared to 4a-4g series against two cell 
lines. Particularly, compounds possessing 
chloro and methoxy substitutions on phenyl 
ring at para position (5c and 5f) showed 
highest antiproliferative activity against HT-
29 and PC-3 cell lines with IC50 values rang-
ing from 6.43 µM to 10.15 µM as compared 
to corresponding ortho substituted com-
pounds (5b and 5e). However, compounds 
with methyl substitution at para position (4d 
and 5d), compounds 4a and 5a, and napthyl 
derivatives (4g and 5g) exhibited less anti-
proliferative activity.  
 
Evaluation of angioinhibitory activity by 
CAM Assay  
The antiangiogenic activity was screened 
by observing microvessel density (MVD) 
count, which is important tool to assess the 
neovasculature in tumors. Vehicle control 
group was treated with 0.1 % DMSO did not 
show any change in vasculature. CAM assay 
results showed reduced MVD count for the 
synthesized pyrazole derivatives. There is 
remarkable correlation observed between the 
docking studies and angioinhibitory activity. 
Among the tested compounds, compound 5c
 
 
Table 1: In vitro antiproliferative activity of synthesized compounds against two cell lines 
Compound Ar 
IC50 ( µM )a 
HT-29 PC-3 
Doxorubicin - 2.24 ± 0.02 3.86 ± 0.06 
4a C6H5 >100 >100 
4b 2-Cl-C6H4 15.87 ± 0.19 19.47 ± 0.39 
4c 4-Cl-C6H4 14.08 ± 0.42 16.28 ± 0.35 
4d 4-CH3-C6H4 60.66 ± 0.48 88.65 ± 0.46 
4e 2-OCH3-C6H4 34.83 ± 0.23 46.53 ± 0.31 
4f 4-OCH3-C6H4 12.68 ± 0.24 14.29 ± 0.13 
4g Napthyl 87.22 ± 0.85 91.23 ± 0.95 
5a C6H5 86.26 ± 0.74 70.25 ± 0.52 
5b 2-Cl-C6H4 11.64 ± 0.10 18.23 ± 0.41 
5c 4-Cl-C6H4 6.43 ± 0.12 9.83 ± 0.23 
5d 4-CH3-C6H4 40.64 ± 0.82 48.34 ± 0.42 
5e 2-OCH3-C6H4 28.84 ± 0.86 34.85 ± 0.66 
5f 4-OCH3-C6H4 7.23 ± 0.22 10.15 ± 0.23 
5g Napthyl 63.62 ± 0.69 87.68 ± 0.72 
a) Mean value ± standard deviation from 3 independent experiments. 
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exhibited the lowest MVD count showed 
significant docking interactions with the 
VEGFR-2 active site (Figure 2).  
 
Evaluation of in vivo antitumor activity 
against EAC  
Based on promising results obtained in 
early assays (in vitro and CAM), compounds 
were selected namely 4b, 4c, 4f, 5b, 5c and 
5f for in vivo anticancer against EAC bearing 
mice. The reduction in viable tumor cell 
count, MST, and %ILS are important mea-
sures that have been used in this in vivo test-
ing. 5-Flurouracil (20 mg/kg body weight) 
was used as standard drug. Obtained results 
were shown in Table 2. 
 
 
 
Figure 2: (A) Two-dimensional representation of the interacting mode of 5c with VEGFR-2 kinase. (B) 
Three-dimensional structural model of compound 5c (purple) into VEGFR-2 kinase 
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Table 2: In vivo antiproliferative activity of 4b, 4c, 4f, 5b, 5c and 5f against EAC bearing mice 
Group MST (days) ± SEa) ILS ( %) Tumor volume (mL) Viable cells in  ascetic fluid ( %) 
I - - - - 
II 18.5 ± 0.23 - 3.4 ± 0.2 94.5 ± 3.6 
III 36.6 ± 0.48* 97.83 0.9 ± 0.02 18.1 ± 1.8 
IV 24.5 ± 0.96* 32.43 2.5 ± 0.06 47.2 ± .1.3 
V 26.2 ± 1.21* 41.62 2.3 ± 0.06 46.5 ± 1.4 
VI 27.0 ± 1.25* 45.94 2.2 ± 0.04 44.6 ± 1.5 
VII 28.6 ± 1.23* 54.59 2.0 ± 0.05 40.6 ± 1.7 
VIII 32.4 ± 0.53* 75.13 1.7 ± 0.03 33.5 ± 1.6 
IX 30.3 ± 1.58* 63.78 1.9 ± 0.02 38.9 ± 1.4 
a ) Standard error; Significant values are compared to the control group (n=6), *P<0.001 
 
Effect on survival time 
All in vivo tested compounds showed 
significant increase in MST and % ILS as 
compared to EAC control (Table 2). Com-
pound 5c exhibited higher antitumor activity 
and showed 32.4 ± 0.53 days of MST with 
75.13 % ILS as compared to rest of the com-
pounds in the series (5a-5g and 4a-4g). 
Compound 5f showed better 30.3 ± 1.58 
days of MST with 63.78 % ILS as compared 
to compound 5b (28.6 ± 1.23 days of MST 
with 54.59 % ILS). Whereas, compounds 4f 
(27.0 ± 1.25 days of MST with 45.94 % 
ILS), and 4c (26.2 ± 1.21 days of MST with 
41.62 % ILS) displayed moderate activity. 
 
Tumor volume and viable cells 
Antitumor activity of tested compounds 
on EAC bearing mice in vivo was further 
studied in terms of tumor volume and num-
ber of viable cells. Almost, all the tested 
compounds exhibited significant decrease in 
tumor volume and cell number as compared 
to EAC control. Compound 5c, which exhib-
ited highest, % ILS, demonstrated maximum 
reduction of viable cells (33.5 ± 1.6 %) and 
tumor volume (1.7 ± 0.03 mL) as compared 
to rest of the compounds. 
 
Docking studies  
Virtual pyrazole derivatives (Figure 3) 
showing significant interactions in molecular 
docking, this provided guidance for selection 
of derivatives to be synthesized for better an-
tiproliferative activity. Literature survey re-
veals that, VEGFR-2 kinase inhibitors 
known to interact with amino acids such as 
Asp 1046, Glu 885, Cys 1045, Val 895, Arg 
1027, Phe 1047, Ile 1025, etc., at the active 
site. While Asp 1046, Glu 885, and Arg 
1027 tend to form hydrogen bonds with the 
ligand, Phe 1047 and Val 899 undergo stack-
ing interactions with aromatic ring of ligand 
(Meenakshi et al., 2013; Sanphanya et al., 
2013; Borzilleri et al., 2005; Dai et al., 
2008). In the present study, the designed 
structures were docked into VEGFR-2 ki-
nase active site to explore to know that ex-
perimental compounds have similar interac-
tions as that of known VEGFR-2 inhibitors. 
Docking of compound 4f showed two hy-
drogen bond interactions (NH of ring D and 
Ile 1044; d=1.88 Ao, OCH3 of ring B and 
Lys 868; d=3.06 Ao) and ring C showed 
stacking interaction with Arg 1027 (d=3.64 
Ao). Moreover, ring B was surrounded by 
Asp 1046 and Glu 885 and this may be the 
reason for superior activity of compound 4f 
among the series 4a-4g in antiproliferative 
studies. Compound 4e, though it does not 
show any hydrogen bond interactions in 
docking, but elicited moderate antiprolifera-
tive activity studies, which might be due to 
its close association with active site amino 
acids such as Asp 1046, Lys 868, His 1026 
and Glu 885. Compound 5c exhibited three 
hydrogen bond interactions (oxygen of OH 
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and Arg 1027; d=2.28 Ao, hydrogen of OH 
and Ile 1025; d=1.23 Ao, C=O and Ile 1025; 
d=2.89 Ao) and ring D stacking interaction 
with Arg 1027. Apart from this, compound 
was surrounded by Asp 1046, Glu 885 and 
Lys 868. The introduction of -CH2COOH in 
the series 5a-5g provided additional hydro-
gen bond interactions with the active site 
amino acids of VEGFR-2 and this might 
have contributed for better activity of these 
series as compared to other series of com-
pounds 4a-4g, which is supported by results 
obtained in antiangiogenesis, in vitro and in 
vivo antiproliferative activity. Data pertain-
ing to the interaction of pyrazolyl tetrazoles 
4a-4g and pyrazolyl tetrazole acetic acids 
5a-5g with active site amino acids of 
VEGFR-2 was given in Table 3. The two-
dimensional and three-dimensional represen-
tations of compound 5c and 4f were given 
under Figures 2 and 4. 
 
Structure activity relationship study (SAR)  
Structure activity relationship was car-
ried out according to the results of in vitro 
and in vivo antiproliferative activity of the 
screened compounds. It is interesting to note 
that 5a-5g series have more antiproliferative 
activity as compared to that of 4a-4g series 
against tested cell lines and EAC bearing 
mice. Particularly, compound 5c possessing 
para chloro on phenyl ring showed more po-
tent activity against two cell lines HT-29 and 
PC-3, and EAC in vivo as compared to ortho 
chloro substitution on phenyl ring (5b). 
However, para methoxy group on the phenyl 
ring (5f) demonstrated better in vitro activity 
as compared to ortho methoxy derivatives 
(5e). In the series of the pyrazole tetrazolyl 
derivatives, para methoxy substitution on the 
phenyl ring (4f) exhibited significant in vitro 
and moderate in vivo antiproliferative activi-
ty. Moreover, chloro substitution at para and 
ortho positions (4c and 4b) showed slightly 
less activity as compared to (4f). Methyl 
substitution at para position (4d and 5d), 
compounds with unsubstituted (4a and 5a), 
and napthyl derivatives (4g and 5g) showed 
less antiproliferative activity.  
N
N
N
N
N
N
CH2COOH
B D
C
A
 
Figure 3: General structure of designed pyrazole 
derivatives 
 
 
Table 3: Interaction of pyrazolyl tetrazoles 4a-4g 
and pyrazolyl tetrazole acetic acids 5a-5g with 
active site amino acids of VEGFR-2 receptor 
Com-
pound 
Interaction with amino acids of 
VEGFR-2 
4a Asp1046, Lys868  (surrounded by Glu885) 
4b Glu885 (surrounded by Asp1046, His1026) 
4c Asp1046, Lys868  (surrounded by Glu885) 
4d Asp1046, Lys868  (surrounded by Glu885) 
4e Surrounded by Asp1046,  Lys868,His 1026, Glu885 
4f Lys868, Ile1044, Arg1027  (surrounded by Glu885, Asp1046) 
4g Surrounded by Asp1046,  His1026, Arg1027 
5a 
Ile1025, Lys868 (surrounded by 
Glu885, Asp1046, Arg1027, 
His1026) 
5b Arg1027, His1026, Lys868  (surrounded by Glu885,Asp1046) 
5c Arg1027, Ile1025 (surrounded by Glu885,Asp1046,Lys868) 
5d Lys868 
5e Arg1027,Arg819 (surrounded by  Asp1046,His1026,His816) 
5f 
Ser884, Arg1027, Ile1025  
(surrounded by Glu885, Asp1046, 
Lys868, His1026) 
5g Arg1027, Ile1025 
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Figure 4: (A) Two-dimensional representation of the interacting mode of 4f with VEGFR-2 kinase. (B) 
Three-dimensional structural model of compound 4f (purple) into VEGFR-2 kinase 
 
 
Toxicity prediction by bioclipse 
Bioclipse online software was used for 
the prediction of the overall toxicity of the 
new compounds before they are being syn-
thesized and screened for activity. The pre-
diction strategies rely on efficient mapping 
of complementary data coming from differ-
ent data set into a unifying structure having 
shared terminology and representation. Mu-
tagenicity is the ability of a substance to in-
duce mutations by interacting with DNA and 
to change its structure. A carcinogen is a 
type of mutagen that specifically causes can-
cer and aquatic toxicology parameter is 
meant to study the effects of manufactured 
chemicals on aquatic organisms.  
Site of metabolism prediction process fo-
cuses on pinpointing the site or moiety in a 
chemical structure, which is most likely to 
undergo metabolization, hence aiding with 
decision support in the drug optimization 
process. A positive result implies susceptibil-
ity of the moiety for metabolism. Negative 
results indicate the resistance of the moiety 
for undergoing metabolism. Cytochrome 
P450 (CYP) isoforms are responsible for me-
tabolism of many drugs. Inhibition of this 
CYP isoforms results in decreased elimina-
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tion and change in metabolic pathways of 
their substrates, which is the major cause of 
adverse drug-drug interactions. It is, there-
fore, essential to trace out the compounds 
potential for CYP inhibition at an early stage 
of drug discovery. The ability of the de-
signed compounds to inhibit five major drug 
metabolizing CYP isoforms (i.e. CYP3A4, 
CYP2D6, CYP2C19, CYP2C9 and 
CYP1A2) was predicted by using a unified 
proteochemometric (PCM) model in bio-
clipse software. A positive result implies that 
compound computationally predicted to in-
hibit CYP isoforms and the negative sign in-
dicates that the compound computationally 
predicted to have no ability to inhibit CYP 
isoforms. The designed pyrazolyl tetrazoles 
4a-4g and 5a-5g have shown differential ef-
fect on the inhibition of CYP isoforms. 
While compounds 4a-4c predicted to show 
positive on the inhibition of CYP isoforms 
and the remaining compounds exhibited 
negative effect. It can be assumed that the 
presence of –CH2COOH moiety in 5a-5g se-
ries may be responsible for the negative ef-
fect on inhibition of CYP isoforms. The re-
sults displayed in Table 4, showed that all 
the compounds are likely to exhibit low 
probable toxicity risks as revealed by com-
putational in silico studies. 
 
 
Table 4: Predicted toxicity parameters of synthesized 4a-4g and 5a-5g compounds 
Com-
pound 
Toxicitya) Metabolism 
Mutageniciy Carcinogen-icity 
Aquatic 
toxicity 
Site of 
metabolism CYP PCM 
4a Negativeb) Negativeb) Negativeb) Positived) Positivee) 
4b Negativeb) Negativeb) Negativeb) Positived) Positivee) 
4c Negativeb) Negativeb) Negativeb) Positived) Positivee) 
4d Negativeb) Negativeb) Negativeb) Positived) Negative f) 
4e Negativeb) Inconclusivec) Negativeb) Positived) Negative f) 
4f Negativeb) Inconclusivec) Negativeb) Positived) Negative f) 
4g Negativeb) Negativeb) Negativeb) Positived) Negative f) 
5a Negativeb) Negativeb) Negativeb) Positived) Negative f) 
5b Negativeb) Negativeb) Negativeb) Positived) Negative f) 
5c Negativeb) Negativeb) Negativeb) Positived) Negative f) 
5d Negativeb) Negativeb) Negativeb) Positived) Negative f) 
5e Negativeb) Negativeb) Negativeb) Positived) Negative f) 
5f Negativeb) Inconclusivec) Negativeb) Positived) Negative f) 
5g Negativeb) Negativeb) Negativeb) Positived) Negative f) 
a) Toxicity parameters are computed by the on-line software Bioclipse 
b) Negative: Compound computationally predicted to be safe 
c) Inconclusive: Compound computationally predicted to be uncertain about the toxicity  
d) Positive: Compound computationally predicted to be susceptible for metabolism 
e) Positive: Compound computationally predicted to inhibit CYP isoforms 
f) Negative: Compound computationally predicted to have no inhibitory effect on CYP isoforms 
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Assessment of lipophilicity and drug score 
profiles 
Osiris program was used for prediction 
of the C log P of the designed derivatives. C 
Log P is a well-established parameter to 
measure the compound hydrophilicity. Com-
pounds show reasonable probability of being 
well absorbed, when they have C log P value 
less than 5.0. It is well established that 80 % 
of the drugs on the market have log S value 
around -4.0. From the table, it was observed 
that all designed compounds have shown C 
log P less than 5.0 and most of the com-
pounds have log S values around -4.0 indi-
cating that the synthesized compounds could 
be possible drug candidates. The drug score 
combines C Log P, Log S, molecular weight 
and toxicity risks in one handy value that 
may be used to judge the compounds overall 
potential to qualify for a drug. A value 
around 0.5 makes this compound a promis-
ing lead for future development of safe and 
efficient drug. Predictions of C log P, solu-
bility, and drug score for the title compounds 
are given in Table 5 and almost all the de-
signed compounds possess good values of 
drug score. 
 
CONCLUSION 
A novel series of pyrazolyl tetrazoles 4a-
4g and pyrazolyl tetrazole acetic acids 5a-5g 
were designed, synthesized and evaluated for 
in vitro antiproliferative activity against two 
cell lines and angioinhibitory activity in 
CAM assay. Based on the obtained results of 
in vitro and CAM assays, compounds were 
selected for in vivo studies. Among the tested 
derivatives, compound possessing para chlo-
ro substitution on phenyl ring (5c), which 
showed significant activity in vitro and in vi-
vo potency, also exhibited better angioinhibi-
tory activity. Assessment of toxicities and 
drug score profiles of designed compounds 
are promising. Moreover, the synthesized 
compounds showed significant docking in-
teractions with VEGFR-2 active site. All the 
results showed that the tested compounds 
may lead to discovery of potent anticancer 
agents for further optimization. 
Table 5: Computationally predicted lipophilicity, 
solubility and drug score of the designed com-
pounds  
Compound C log Pa) Log Sb) Drug score 
4a 1.77 -4.41 0.55 
4b 2.38 -5.15 0.54 
4c 2.38 -5.15 0.59 
4d 2.08 -4.76 0.42 
4e 1.66 -4.43 0.57 
4f 1.66 -4.43 0.58 
4g 2.95 -6.02 0.29 
5a 1.29 -3.21 0.51 
5b 1.90 -3.95 0.50 
5c 1.90 -3.95 0.55 
5d 1.60 -3.55 0.43 
5e 1.18 -3.23 0.52 
5f 1.18 -3.23 0.53 
5g 2.47 -4.82 0.30 
a) Calculated lipophilicity 
b) Solubility parameter 
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